Unexpected focal fluorodeoxyglucose uptake in main organs; pass through or pass by?
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Haejun | - |
dc.contributor.author | Hwang, Kyung-Hoon | - |
dc.date.accessioned | 2024-06-04T06:30:30Z | - |
dc.date.available | 2024-06-04T06:30:30Z | - |
dc.date.issued | 2024-04 | - |
dc.identifier.issn | 2307-8960 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/91425 | - |
dc.description.abstract | Since the inception of fluorine-18 fluorodeoxyglucose (F-18 FDG), positron emission tomography/computed tomography (PET/CT) utilizing F-18 FDG has become widely accepted as a valuable imaging modality in the field of oncology, with global prevalence in clinical practice. Given that a single Torso PET/CT scan encompasses the anatomical region from the skull base to the upper thigh, the detection of incidental abnormal focal hypermetabolism in areas of limited clinical interest is both feasible and not uncommon. Numerous investigations have been undertaken to delineate the distinctive features of these findings, yet the outcomes have proven inconclusive. The incongruent results of these studies present a challenge for physicians, leaving them uncertain about the appropriate course of action. This article provides a succinct overview of the characteristics of fluorodeoxyglucose, followed by a comprehensive discussion of the imaging findings and clinical significance associated with incidental focal abnormal F-18 FDG activity in several representative organs. In conclusion, while the prevalence of unrecognized malignancy varies across organs, malignancies account for a substantial proportion, ranging from approximately one-third to over half, of incidental focal uptake. In light of these rates, physicians are urged to exercise vigilance in not disregarding unexpected uptake, facilitating more assured clinical decisions, and advocating for further active evaluation. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | BAISHIDENG PUBLISHING GROUP INC | - |
dc.title | Unexpected focal fluorodeoxyglucose uptake in main organs; pass through or pass by? | - |
dc.type | Article | - |
dc.identifier.wosid | 001208063300013 | - |
dc.identifier.doi | 10.12998/wjcc.v12.i11.1885 | - |
dc.identifier.bibliographicCitation | WORLD JOURNAL OF CLINICAL CASES, v.12, no.11 | - |
dc.description.isOpenAccess | Y | - |
dc.citation.title | WORLD JOURNAL OF CLINICAL CASES | - |
dc.citation.volume | 12 | - |
dc.citation.number | 11 | - |
dc.type.docType | Review | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | Incidental | - |
dc.subject.keywordAuthor | Focal | - |
dc.subject.keywordAuthor | Incidentaloma | - |
dc.subject.keywordAuthor | Fluorodeoxyglucose | - |
dc.subject.keywordAuthor | Positron emission tomography | - |
dc.subject.keywordAuthor | Hypermetabolism | - |
dc.subject.keywordPlus | POSITRON-EMISSION-TOMOGRAPHY | - |
dc.subject.keywordPlus | STANDARDIZED UPTAKE VALUE | - |
dc.subject.keywordPlus | INCREASED F-18-FDG UPTAKE | - |
dc.subject.keywordPlus | DIFFERENTIATED THYROID-CARCINOMA | - |
dc.subject.keywordPlus | BREAST-CANCER STATISTICS | - |
dc.subject.keywordPlus | BRAF V600E MUTATION | - |
dc.subject.keywordPlus | FDG-PET | - |
dc.subject.keywordPlus | CLINICAL-SIGNIFICANCE | - |
dc.subject.keywordPlus | UPTAKE VALUES | - |
dc.subject.keywordPlus | COMPUTED-TOMOGRAPHY | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.description.journalRegisteredClass | scie | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.